Abstract | UNLABELLED:
Botulinum toxin type A is one of the most potent biological toxins, recently used clinically ( Botox, Dysport) for wide range of indications. THE AIM OF THE STUDY was to assess the frequency and severity of side effects during BTX-A therapy for different indications and underlying possible mechanisms. MATERIAL AND METHODS: RESULTS: In CD the following side effects were observed: dysphagia (27% of patients and 7% of sessions), weakness of neck muscles (6.7% and 1.3%), pain during swallowing (5.1% and 1%), flu-like syndrome (3.4%, 0.7%). Dysphagia appeared 8.2 days after injection and lasted 14.9 days on average. In BLP authors noticed: unilateral ptosis (22%, 6.3%), bilateral ptosis (3%, 1.9%), haematoma (3%, 0.6%) and in HFS: excessive weakness resulting in asymmetry of face--mild (28.2% and 20%) and moderate (46% and 26.7%). In spasticity due to CP authors noticed: excessive weakness of lower limbs which lasted 13.8 days on average (6.2% and 1.9%), pain (5.2% and 1.6%), flu-like syndrome (4.1% and 1.3%). In CAF: mild incontinence of the flatus and faeces (9% and 5% of sessions), haematoma (5%), flu-like syndrome (3%), inflammation of external anal varices (2%), epididymitis (1%). In AE: chest pain in 6 (at the day of injection and lasted 2-4 days) and reflux in 2 patients (4-8 weeks after injection, lasted 2-3 weeks) were observed. CONCLUSION:
Therapy with BTX-A is a very safe procedure, especially when compared with high rate of effectiveness of injections. The side effects are transient, mostly local and completely reversible.
|
Authors | Jarosław Sławek, Mariusz H Madaliński, Iwona Maciag-Tymecka, Wojciech Duzyński |
Journal | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
(Pol Merkur Lekarski)
Vol. 18
Issue 105
Pg. 298-302
(Mar 2005)
ISSN: 1426-9686 [Print] Poland |
Vernacular Title | Analiza czestości wystepowania objawów ubocznych po podaniu toksyny botulinowej typu A w neurologii, rehabilitacji i gastroenterologii. |
PMID | 15997637
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Blepharoptosis
(chemically induced)
- Botulinum Toxins, Type A
(administration & dosage, adverse effects)
- Child
- Child, Preschool
- Deglutition Disorders
(chemically induced)
- Dystonic Disorders
(drug therapy)
- Esophageal Achalasia
(drug therapy)
- Female
- Fissure in Ano
(drug therapy)
- Hemifacial Spasm
(drug therapy)
- Humans
- Incidence
- Male
- Middle Aged
- Muscle Spasticity
(drug therapy)
- Muscle Weakness
(chemically induced)
- Muscles
(drug effects)
- Neuromuscular Agents
(administration & dosage, adverse effects)
|